Department of Radiation Oncology, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Department of Neurological Surgery, Oregon Health & Sciences University, Portland, OR, USA.
Br J Neurosurg. 2020 Dec;34(6):690-696. doi: 10.1080/02688697.2019.1710820. Epub 2020 Jan 14.
Recent studies of primary central nervous system lymphoma (PCNSL) have found a positive association between cytoreductive surgery and survival, challenging the traditional notion that surgery is not beneficial and potentially harmful. However, no studies have examined the potential added benefits of adjuvant treatment in the post-operative setting. Here, we investigate survival in PCNSL patients treated with surgery plus radiation therapy (RT). The Surveillance, Epidemiology, and End-Results Program was used to identify patients with PCNSL from 1995-2013. We retrospectively analyzed the relationship between treatment, prognostic factors, and survival using case-control design. Treatment categories were compared to biopsy alone. We identified 5417 cases. Median survival times for biopsy alone ( = 1824, 34%), biopsy + RT ( = 1460, 27%), surgery alone ( = 1222, 27%), and surgery + RT ( = 911, 17%) were 7, 8, 20, and 27 months, respectively. On multivariable analysis, surgery + RT was associated with improved survival over surgery alone (hazard ratio [HR] = 0.58 [95% confidence interval = 0.53-0.64] vs. HR = 0.71 [0.65-0.77]). Adjuvant RT was associated with improved survival, regardless of the extent of resection. HR's for subtotal resection, gross-total resection, subtotal resection + RT, and gross-total resection + RT were 0.77 (0.66-0.89), 0.66 (0.57-0.76), 0.62 (0.52-0.72), and 0.54 (0.46-0.63), respectively. Survival improved after adjuvant RT in patients under and over 60 years old. All findings were confirmed by multivariable analysis of cause-specific survival. Adjuvant RT was associated with improved survival in PCNSL patients who underwent surgery. Although these data are hypothesis-generating, additional information on neurotoxicity, dosing, and concurrent chemotherapy will be necessary to validate these findings. Cytoreductive surgery for PCNSL is common in the general population, and more studies are needed to assess optimal treatment in the post-operative setting.
最近对原发性中枢神经系统淋巴瘤(PCNSL)的研究发现,细胞减灭手术与生存之间存在正相关,这挑战了传统观念,即手术无益且可能有害。然而,尚无研究探讨辅助治疗在术后环境中的潜在获益。在此,我们研究了接受手术加放疗(RT)治疗的 PCNSL 患者的生存情况。利用监测、流行病学和最终结果计划,从 1995 年至 2013 年确定了 PCNSL 患者。我们使用病例对照设计回顾性分析了治疗、预后因素与生存之间的关系。治疗类别与单独活检进行比较。我们共鉴定了 5417 例患者。单独活检( = 1824 例,34%)、活检 + RT( = 1460 例,27%)、单纯手术( = 1222 例,27%)和手术 + RT( = 911 例,17%)的中位生存时间分别为 7、8、20 和 27 个月。多变量分析显示,与单纯手术相比,手术 + RT 可改善生存(风险比 [HR] = 0.58 [95%置信区间为 0.53-0.64] vs. HR = 0.71 [0.65-0.77])。辅助 RT 可改善生存,无论切除范围如何。次全切除、大体全切、次全切除 + RT 和大体全切 + RT 的 HR 分别为 0.77(0.66-0.89)、0.66(0.57-0.76)、0.62(0.52-0.72)和 0.54(0.46-0.63)。60 岁以下和 60 岁以上患者接受辅助 RT 后生存均得到改善。所有结果均通过对特定原因的生存进行多变量分析得以确认。辅助 RT 可改善接受手术的 PCNSL 患者的生存。尽管这些数据是假设生成的,但为了验证这些发现,还需要更多关于神经毒性、剂量和联合化疗的信息。PCNSL 患者的细胞减灭手术在普通人群中很常见,需要更多的研究来评估术后的最佳治疗方法。